Hikma enters the Spanish generic injectables market, strengthening its European presence
London, 20 May 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is pleased to announce the establishment of HIKMA ESPAÑA, S.L.U. (Hikma Spain). This marks Hikma’s official entry into Spain, which has a generic injectable market size of approximately $860 million1.
In the year to date, Hikma has received 36 product approvals and launched 25 products in Spain. These span several therapeutic areas including cardiovascular, oncology, central nervous system and anti-infectives.
The entry into the Spanish market strengthens the Group’s established and growing presence in Europe. This includes high-quality manufacturing plants in Portugal, Italy and Germany, which supply injectable products to North America, Europe, and Middle East and North Africa.
Hikma is already supporting the Spanish hospitals by providing key oncological molecules that are currently in shortage.
Dr Bill Larkins, President of Hikma Injectables commented:
“The expansion into Spain is another important milestone in our global strategy to grow and strengthen our Injectables’ commercial presence in Europe and around the world. We have an agile supply chain, a growing product portfolio and regional manufacturing capabilities, which will enable us to supply Spanish hospitals and their patients with the high-quality injectable medicines they need. We look forward to building our presence here.”
Carola Warleta, Commercial Head, Hikma Spain commented:
“We are launching the Spanish affiliate at a time when the hospital sector is in need of a reliable and quality supplier. I am confident in our ability to work hand in hand with healthcare professionals and authorities to provide high-quality and affordable medicines to patients in Spain.”
1 IQVIA 2023 USD Sales. Generic Injectable, Hospital Sector.